Levemir: adverse event reports filed with FDA

13,652

reports as suspect product

0.1% of all reports · about 640 a year

671

reports, 12 months to June 2026

539 in the 12 months before

54.8%

marked serious by the reporter

42.7% across the class

3.4%

record death among outcomes, as reported

463 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Levemir reports recording the termmedian drug in insulin analog

1. Blood glucose increasedraised blood sugar reading23.7%3,237
2. Blood glucose decreasedlow blood sugar reading5.7%781
3. Hypoglycaemialow blood sugar4.4%595
4. Dizzinesslight-headedness or unsteadiness2.7%370
5. Cerebrovascular accidentstroke2.7%362
6. Malaisegeneral feeling of being unwell2.6%353
7. Drug ineffectivethe medicine did not work as expected2.5%344
8. Glycosylated haemoglobin increaseda raised HbA1c, the long-term sugar measure2.5%335
9. Diabetes mellitus inadequate controldiabetes not well controlled2.2%307
10. Visual impairmentreduced vision2.2%305
11. Falla fall2.2%304
12. Injection site painpain where the injection was given2.2%304
13. Foetal exposure during pregnancythe unborn baby was exposed to the medicine2.2%296
14. Nauseafeeling sick2%279
15. Blood glucose fluctuation2%278
16. Weight decreasedweight loss1.9%264
17. Fatiguetiredness1.9%255
18. Diabetic ketoacidosisa serious complication of diabetes with acid build-up1.8%250
19. Injection site erythemaredness where the injection was given1.8%249
20. Dyspnoeashortness of breath1.8%242
21. Headachehead pain1.7%238
22. Arthritis1.7%236
23. Weight increasedweight gain1.7%234
24. Pruritusitching1.7%230
25. Device malfunctionthe device did not work properly1.6%216
26. Vomitingbeing sick1.5%210
27. Injection site mass1.5%205
28. Device failurethe device failed1.5%202
29. Astheniaweakness or lack of energy1.5%198
30. Rashskin rash1.4%194

Top 30 of 1,016 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 26 drugs in the insulin analog class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 289,293 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 80% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 13,652 reports.

Drugs most often listed in the same reports

Other products listed in reports where Levemir is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the insulin analog class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Levemir as a suspect or interacting product; reports listing it only as a concomitant medication (23,399) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.